Wall Street Experts
ver. ZuMIgo(08/25)
Kymera Therapeutics, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 88
EBIT TTM (mln): -167
| index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
| Rok finansowy |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Przychód (mln) |
0 |
3 |
34 |
73 |
47 |
79 |
47 |
| Przychód Δ r/r |
0.0% |
inf% |
1060.0% |
114.0% |
-35.7% |
67.8% |
-40.1% |
| Marża brutto |
0.0% |
71.9% |
-82.5% |
96.7% |
93.6% |
95.5% |
100.0% |
| EBIT (mln) |
-21 |
-42 |
-46 |
-101 |
-161 |
-166 |
-262 |
| EBIT Δ r/r |
0.0% |
96.8% |
9.7% |
117.1% |
60.4% |
2.7% |
58.1% |
| EBIT (%) |
0.0% |
-1438.5% |
-136.1% |
-138.0% |
-344.4% |
-210.6% |
-555.8% |
| Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EBITDA (mln) |
-21 |
-40 |
-45 |
-100 |
-155 |
-143 |
-216 |
| EBITDA(%) |
0.0% |
-1376.1% |
-133.6% |
-137.4% |
-330.2% |
-182.2% |
-459.4% |
| Podatek (mln) |
0 |
0 |
-2 |
-2 |
-3 |
19 |
0 |
| Zysk Netto (mln) |
-21 |
-41 |
-44 |
-98 |
-152 |
-147 |
-224 |
| Zysk netto Δ r/r |
0.0% |
92.4% |
6.4% |
123.0% |
54.9% |
-3.2% |
52.3% |
| Zysk netto (%) |
0.0% |
-1407.4% |
-129.1% |
-134.5% |
-324.2% |
-187.0% |
-475.6% |
| EPS |
-1.07 |
-0.93 |
-2.53 |
-2.04 |
-2.82 |
-2.52 |
-2.98 |
| EPS (rozwodnione) |
-1.07 |
-0.93 |
-2.53 |
-2.04 |
-2.82 |
-2.52 |
-2.98 |
| Ilośc akcji (mln) |
20 |
45 |
17 |
48 |
54 |
58 |
75 |
| Ważona ilośc akcji (mln) |
20 |
45 |
17 |
48 |
54 |
58 |
75 |
| Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |